MedPath
HSA Approval

MONTELUKAST-TEVA FC TABLET 10 MG

SIN16431P

MONTELUKAST-TEVA FC TABLET 10 MG

MONTELUKAST-TEVA FC TABLET 10 MG

February 25, 2022

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Therapeutic

Prescription Only

Formulation Information

TABLET, FILM COATED

**DOSAGE AND ADMINISTRATION** MONTELUKAST-TEVA should be taken once daily. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs. Patients with both asthma and allergic rhinitis should take only one tablet daily in the evening. _**Adults 15 Years of Age and Older with Asthma and/or Allergic rhinitis**_ The dosage for adults 15 years of age and older is one 10-mg tablet daily. _General Recommendations_ The therapeutic effect of Montelukast on parameters of asthma control occurs within one day. Montelukast tablets can be taken with or without food. Patients should be advised to continue taking Montelukast tablets while their asthma is controlled, as well as during periods of worsening asthma. No dosage adjustment is necessary for the elderly, for patients with renal insufficiency, or mild-to-moderate hepatic impairment, or for patients of either gender. _Therapy with Montelukast in Relation to Other Treatments for Asthma_ Montelukast can be added to a patient’s existing treatment regimen. Reduction in Concomitant Therapy: _Bronchodilator Treatments:_ Montelukast can be added to the treatment regimen of patients who are not adequately controlled on bronchodilator alone. When a clinical response is evident (usually after the first dose), the patient’s bronchodilator therapy can be reduced as tolerated. _Inhaled Corticosteroids:_ Treatment with Montelukast provides additional clinical benefit to patients treated with inhaled corticosteroids. A reduction in the corticosteroid dose can be made as tolerated. The dose should be reduced gradually with medical supervision. In some patients, the dose of inhaled corticosteroids can be tapered off completely. Montelukast should not be abruptly substituted for inhaled corticosteroids.

ORAL

Medical Information

**INDICATIONS** MONTELUKAST-TEVA is indicated in adults 15 years of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. MONTELUKAST-TEVA is indicated for the relief of daytime and nighttime symptoms of allergic rhinitis (seasonal allergic rhinitis and perennial allergic rhinitis in adults 15 years of age and older). Because the benefits of MONTELUKAST-TEVA may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis, reserve use for patients who have an inadequate response or intolerance to alternative therapies.

**CONTRAINDICATIONS** Hypersensitivity to any component of this product

R03DC03

montelukast

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA Operations Poland Sp. z o.o.

Active Ingredients

Montelukast sodium eqv to Montelukast

10 mg

Montelukast

Documents

Package Inserts

Montelukast Teva Film Coated Tablet PI.pdf

Approved: February 25, 2022

Download
© Copyright 2025. All Rights Reserved by MedPath
MONTELUKAST-TEVA FC TABLET 10 MG - HSA Approval | MedPath